Invention Grant
US09050315B2 In vivo and ex vivo expansion of hematopoietic stem cells with a targeted combination of clinically tested, FDA approved drugs
有权
造血干细胞的体内和体外扩增与临床试验的目标组合，FDA批准的药物
- Patent Title: In vivo and ex vivo expansion of hematopoietic stem cells with a targeted combination of clinically tested, FDA approved drugs
- Patent Title (中): 造血干细胞的体内和体外扩增与临床试验的目标组合，FDA批准的药物
-
Application No.: US13084180Application Date: 2011-04-11
-
Publication No.: US09050315B2Publication Date: 2015-06-09
- Inventor: Peter S. Klein , Jian Huang
- Applicant: Peter S. Klein , Jian Huang
- Applicant Address: US PA Philadelphia
- Assignee: The Trustees of the University of Pennsylvania
- Current Assignee: The Trustees of the University of Pennsylvania
- Current Assignee Address: US PA Philadelphia
- Agency: Riverside Law LLP
- Main IPC: A61K35/28
- IPC: A61K35/28 ; C12N5/0789
Abstract:
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions.
Public/Granted literature
Information query
IPC分类:
